Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 1, 2016, Pages 90-98

  Amiot, Aurélien ^a,b,c   Hulin, Anne ^a,b   Belhassan, Mehdi ^a,b   Andre, Chantal ^a,b,d   Gagniere, Charlotte ^a,b   Le baleur, Yann ^a,b   Farcet, Jean Pierre ^a,b,d   Delchier, Jean Charles ^a,b   Hüe, Sophie ^a,b,d  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c LICS   (France)

^d INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; DRUG ANTIBODY; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASES; PREDICTIVE VALUE; YOUNG ADULT;

ADULT; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; YOUNG ADULT;

EID: 84959497017     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.05.019     Document Type: Article

References (25)

1. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
2. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
3. Allez M., Karmiris K., Louis E., Van Assche G., Ben-Horin S., Klein A., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010, 4:355-366.
4. Chowers Y., Sturm A., Sans M., Papadakis K., Gazouli M., Harbord M., et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010, 4:367-376.
5. Ordas I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087. [quiz e85-6].
6. Vande Casteele N., Compernolle G., Ballet V., Van Assche G., Gils A., Vermeire S., et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) Trial. Gastroenterology 2013, 142:S211-S212.
7. Groupe d'étude thérapeutique des affections inflammatoires du tube digestif (GETAID) Study investigating tailored treatment with infliximab for active Crohn's Disease (TAILORIX) 2013.
8. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
9. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61:1619-1635.
10. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
11. Sandborn W.J., Colombel J.F., D'Haens G., Van Assche G., Wolf D., Kron M., et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013, 37:204-213.
12. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cezard J.P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006, 118:11-19.
13. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
14. Feagan B.G., McDonald J.W., Panaccione R., Enns R.A., Bernstein C.N., Ponich T.P., et al. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease. Gastroenterology 2010, 138:S167-S168.
15. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
16. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
17. Pariente B., Pineton de Chambrun G., Krzysiek R., Desroches M., Louis G., De Cassan C., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
18. Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013, 108:962-971.
19. Ungar B., Chowers Y., Yavzori M., Picard O., Fudim E., Har-Noy O., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2013.
20. Eser A., Primas C., Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol 2013, 29:391-396.
21. Laharie D., Filippi J., Roblin X., Nancey S., Chevaux J.B., Hebuterne X., et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013, 37:998-1004.
22. Colombel J.F., Rutgeerts P., Reinisch W., Esser D., Wang Y., Lang Y., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
23. Jurgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421e1-427e1.
24. Marits P., Landucci L., Sundin U., Davidsdottir L., Nilsson J., Befrits R., et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014, 8:881-889.
25. Paul S., Del Tedesco E., Marotte H., Rinaudo-Gaujous M., Moreau A., Phelip J.M., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013, 19:2568-2576.